AZN

AstraZeneca PLC
D

AZN

73.800
USD
0.95
(1.30%)
Pre Open
Volume
294
EPS
4
Div Yield
2.1
P/E
33
Market Cap
228,804,329,351
Related Instruments
AMGN
AMGN
1.25
(0.41%)
306.95 USD
BMY
BMY
1.120
(1.90%)
60.010 USD
GILD
GILD
0.650
(0.58%)
111.800 USD
GSK
GSK
0.235
(0.61%)
38.750 USD
JNJ
JNJ
0.580
(0.36%)
163.690 USD
LLY
LLY
0.36
(0.04%)
821.56 USD
MRK
MRK
1.630
(1.86%)
89.230 USD
NVS
NVS
1.160
(1.04%)
112.570 USD
PFE
PFE
0.175
(0.70%)
25.190 USD
SNY
SNY
0.900
(1.64%)
55.820 USD
More
News

Title: AstraZeneca PLC

Sector: Healthcare
Industry: Drug Manufacturers - General
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.